Brief: Amicus Therapeutics Announces Positive Long-Term Data From Phase 3 Open-Label Extension Study Of At-Gaa In Late-Onset Pompe Disease At 19Th Annual Worldsymposium™ 2023

Amicus Therapeutics

22/02/2023 22:26

Feb 22 (Reuters) - Amicus Therapeutics Inc  FOLD.O :
    * AMICUS THERAPEUTICS ANNOUNCES POSITIVE LONG-TERM DATA FROM
PHASE
3 OPEN-LABEL EXTENSION STUDY OF AT-GAA IN LATE-ONSET POMPE
DISEASE AT 19TH ANNUAL WORLDSYMPOSIUM™ 2023
    * AMICUS THERAPEUTICS INC - SAFETY PROFILE ALIGNS WITH
PREVIOUSLY
REPORTED DATA
    * AMICUS THERAPEUTICS INC - CONSISTENT REDUCTION IN
BIOMARKERS
CONTINUE TO SUGGEST A POSITIVE EFFECT ON MUSCLE TISSUE

Source text for Eikon:  ID:nGNX43qdkb 
Further company coverage:  FOLD.O 
 ((Reuters.Briefs@thomsonreuters.com;;))